Elicio Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

ELTX$1.61-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Operating expenses:
Research and development	$6,811	$7,006	$13,568	$14,784
General and administrative	3,618	3,085	7,463	6,043
Total operating expenses	10,429	10,091	21,031	20,827
Loss from operations	(10,429)	(10,091)	(21,031)	(20,827)
Other income (expense)
Change in fair value of warrant liabilities	2,483	(859)	1,499	(1,366)
Foreign exchange transaction gain	1	—	14	—
Grant income	—	415	—	415
Interest income	138	168	295	378
Interest expense	(410)	(194)	(817)	(370)
Total other income (expense), net	2,212	(470)	991	(943)
Net loss	(8,217)	(10,561)	(20,040)	(21,770)
Other comprehensive income:
Foreign currency translation adjustment	(4)	74	1	105
Comprehensive loss	$(8,221)	$(10,487)	$(20,039)	$(21,665)
Net loss per common share, basic and diluted	$(0.43)	$(0.66)	$(1.07)	$(1.50)
Weighted average common shares and pre-funded warrants outstanding, basic and diluted	19,244,679	16,059,423	18,731,065	14,513,586

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.